Keros Therapeutics Inc. (KROS) News

Keros Therapeutics Inc. (KROS): $57.57

-0.33 (-0.57%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KROS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 401

in industry

Filter KROS News Items

KROS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest KROS News From Around the Web

Below are the latest news stories about KEROS THERAPEUTICS INC that investors may wish to consider to help them evaluate KROS as an investment opportunity.

Keros Therapeutics, Inc. (KROS) Upgraded to Buy: Here's What You Should Know

Keros Therapeutics, Inc. (KROS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | December 23, 2022

Keros Therapeutics Presents Clinical Data from its KER-050 and KER-047 Programs and Preclinical Data from its KER-050 and ALK2 Inhibitor Programs at the 64th American Society of Hematology Annual Meeting and Exposition

Keros Therapeutics will be hosting a conference call and webcast today, December 12, 2022, at 4:01 p.m. ET.LEXINGTON, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that it presented additional data from

Yahoo | December 12, 2022

Wall Street Analysts Think Keros Therapeutics, Inc. (KROS) Could Surge 95%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 94.9% in Keros Therapeutics, Inc. (KROS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | November 24, 2022

Keros Therapeutics to Present at Upcoming Healthcare Conferences

LEXINGTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in fireside chat presentations at the Piper Sandler 34

Yahoo | November 22, 2022

Wall Street Analysts Believe Keros Therapeutics, Inc. (KROS) Could Rally 96%: Here's is How to Trade

The mean of analysts' price targets for Keros Therapeutics, Inc. (KROS) points to a 96.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | November 8, 2022

Analysts Are Bullish on These Healthcare Stocks: Keros Therapeutics (KROS), Corcept Therapeutics (CORT)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Keros Therapeutics (KROS – Research Report), Corcept Therapeutics (CORT – Research Report) and Alphatec Holdings (ATEC – Research Report) with bullish sentiments. Keros Therapeutics (KROS) H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Keros Therapeutics today and set a price target of $100.00. The company's shares closed last Friday at $48.64. According to TipRanks.

Brian Anderson on TipRanks | November 7, 2022

Keros Therapeutics Presents Preclinical Data from its KER-012 Program at the American Heart Association 2022 Scientific Sessions

LEXINGTON, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced results from a preclinical study of a research form of KER-012 ("RKER-012") on cardiac and pulmonary pathology in an established rat model of pulm

Yahoo | November 7, 2022

Keros Therapeutics to Present at the 64th American Society of Hematology Annual Meeting and Exposition, Including Presenting Data from its Phase 2 Clinical Trials Evaluating KER-050 and KER-047

LEXINGTON, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that five abstracts will be presented from the KER-050 and KER-047 hematology programs at the 64th American Society of Hematology (“ASH”) Annual M

Yahoo | November 3, 2022

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results

LEXINGTON, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today provided a business update and reported financial results for the quarter ended September 30, 2022. “Keros continued to build upon the posi

Yahoo | November 3, 2022

Shareholders have faith in loss-making Keros Therapeutics (NASDAQ:KROS) as stock climbs 10% in past week, taking one-year gain to 13%

These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But investors can...

Yahoo | October 17, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 4.7329 seconds.